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Abstract: The effect of continuous positive airway pressure (CPAP) on cardiovascular events is uncertain
in minimally symptomatic obstructive sleep apnoea. Previous 2-year follow-up data from the Multicentre
Obstructive Sleep Apnoea Intervention Cardiovascular (MOSAIC) trial showed a marginal reduction in
cardiovascular events with CPAP therapy. We now present long-term MOSAIC study follow-up data.
Median (first quartile, third quartile) follow-up was 5.0 (2.2, 5.0) and 3.7 (1.5, 5.0) years for CPAP and
standard care, respectively. Compared to standard care, CPAP had no statistically significant effect on
the risk of cardiovascular events (HR=0.83, p=0.54, 95% CI 0.46–1.51).
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ABSTRACT
The effect of continuous positive airway pressure (CPAP) 
on cardiovascular events is uncertain in minimally 
symptomatic obstructive sleep apnoea. Previous 2- year 
follow- up data from the Multicentre Obstructive Sleep 
Apnoea Intervention Cardiovascular (MOSAIC) trial showed 
a marginal reduction in cardiovascular events with CPAP 
therapy. We now present long- term MOSAIC study follow- 
up data. Median (first quartile, third quartile) follow- up 
was 5.0 (2.2, 5.0) and 3.7 (1.5, 5.0) years for CPAP and 
standard care, respectively. Compared to standard care, 
CPAP had no statistically significant effect on the risk 
of cardiovascular events (HR=0.83, p=0.54, 95% CI 
0.46–1.51).
INTRODUCTION
The Multicentre Obstructive Sleep Apnoea 
Intervention Cardiovascular (MOSAIC) trial 
was a multicentre, randomised controlled 
trial investigating the effect of continuous 
positive airway pressure (CPAP) treatment 
on calculated cardiovascular risk and daytime 
sleepiness in patients with minimally symp-
tomatic obstructive sleep apnoea (OSA). 
Although CPAP improved daytime sleepiness, 
it did not improve calculated cardiovascular 
risk at 6 months.1
Two- year follow- up data of the Oxford 
patients found a statistically significant but 
marginal reduction (absolute reduction 
9.6%, 95% CI 0% to 19%, p=0.05) in new 
cardiovascular events in the CPAP group 
compared with standard care.2 This contrasts 
with the Sleep Apnoea Cardiovascular events 
(SAVE) Study which showed no improvement 
in new cardiovascular events following CPAP 
therapy.3
Despite evidence from observational 
studies, improvement in cardiovascular 
events resulting from CPAP in OSA remains 
unendorsed by randomised controlled trials.4
METHODS
We report long- term follow- up from all 
patients from a single centre of the MOSAIC 
trial. The MOSAIC trial was a multicentre, 
randomised controlled parallel, hospital trial 
in patients with confirmed OSA (oxygen 
desaturation index >7.5/hour) but insuffi-
cient symptoms to mandate CPAP therapy.1
Patients were randomised to standard care 
or auto- adjusting CPAP therapy. The Oxford 
cohort was followed- up for a maximum of 
5 years, and data were collected on new 
cardiovascular events. Data were analysed 
on an intention- to- treat basis. We prospec-
tively recorded the occurrence of new cardio-
vascular events, including those leading 
to death. Cardiovascular events included 
angina, myocardial infarction, hypertension, 
peripheral vascular disease, atrial fibrillation, 
cardiac failure, stroke, transient ischaemic 
attack, coronary intervention and coronary 
artery bypass graft. Event- free survival was 
analysed using the log- rank test and Cox 
proportional HRs with multivariate analyses 
adjusted for age, baseline cardiovascular 
risk score and body mass index (BMI). A per 
protocol analysis was carried out of those 
patients who were randomised to CPAP who 
had usage of >4 hour/night at last follow- up.
At 2- year follow- up 9% and 4% in the stan-
dard care and CPAP arm groups experienced 
new events per year of follow- up.2 In order 
not to miss similar difference event rate over 
5 years, with 80% power and two- sided alpha 
of 0.05, 120 patients were needed.
RESULTS
All 191 patients from a single centre are 
included in this follow- up analysis, with 94 
initially randomised to the CPAP arm and 
97 to the standard care arm. Patient charac-
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patients (46%) randomised to CPAP crossed over and 
stopped CPAP. Those randomised to CPAP and still using 
CPAP had good mean adherence, with median of mean 
usage of 5:51 hours:min/night (Interquartile range 3:22–
6:58) at the end of the follow- up period; and 10 standard 
care subjects (10%) had were using CPAP with median 
of mean usage of 3:32 hours:min/night (Interquartile 
range 1:00–6:55) by the end of the period.
There were 25 cardiovascular events in the CPAP 
group, compared with 32 in the standard care group. 
There was no significant difference in the univariate risk 
of cardiovascular events between CPAP and standard care 
(HR=0.83, p=0.54, 95% CI 0.46 to 1.51, figure 1). Multi-
variate adjustments for age, BMI and baseline cardio-
vascular risk score did not alter these results (HR=0.82, 
p=0.52, 95% CI 0.45 to 1.50). A per protocol analysis of 
the risk of cardiovascular events in patients with CPAP 
usage >4 hour/night was also not significant, compared 
with standard care (HR=1.3, p=0.46, 95% CI 0.61 to 2.94).
DISCUSSION
We have not shown CPAP to significantly impact cardio-
vascular event rates in minimally symptomatic OSA. This 
contrasts with our previous publication showing a reduc-
tion in cardiovascular events after 2 years of follow- up,2 
hence the importance of reporting these longer term 
data. These results are in keeping with the much larger 
SAVE Study,3 which found that CPAP did not reduce cardi-
ovascular events in patients screened for OSA following 
presentation to cardiovascular clinics.
Long- term follow- up in this study was limited by the 
small trial population, and thus wide confidence intervals 
of the estimates. However, given the marginal reduction 
in cardiovascular events observed at the 2 year follow- up, 
these data are important to report. The median length 
of follow- up was also longer in the CPAP arm as these 
patients were motivated to stay in touch to maintain their 
equipment. However, survival analyses take length of 
follow- up into account.
Table 1 Patient characteristics by treatment group. Data are displayed as mean±standard deviation, median (first quartile, 
third quartile) or number (%)
CPAP Standard care
CPAP where usage 
>4 hour/night
Number 94 97 25
Baseline age (years) 58.2±7.1 57.7±7.6 57.2±6.3
Male 81 (86%) 84 (87%) 23 (92%)
Female 13 (14%) 13 (13%) 2 (8%)
Baseline BMI (kg/m2) 32.6±5.7 32.4±5.3 32.5±4.0
ODI at presentation 10.7 (4.7, 17.9) 10.1 (5.9, 18.2) 11.5 (3.6, 30.4)
Baseline hypertension 45 (48%) 47 (49%) 10 (40%)
Baseline diabetes mellitus 15 (16%) 24 (25%) 3 (12%)
Baseline atrial fibrillation 4 (4%) 4 (4%) 1 (4%)
Baseline ischaemic heart disease 11 (12%) 18 (19%) 2 (8%)
Baseline cerebrovascular disease 6 (6%) 2 (2%) 2 (8%)
Current smoker 10 (11%) 17 (18%) 24 (17%)
Length of follow- up (years) 5.0 (2.2, 5.0) 3.7 (1.5, 5.0) 5.0 (5.0, 5.0)
Number of crossovers 43 (46%) 16 (17%) 0 (0%)
Numbers using CPAP at final follow- up 38 (40%) 10 (10%) 25 (100%)
Adherence in those using CPAP at final follow- up 
(hours:min/night)
5:51 (3:22, 6:58) 3:32 (1:00, 6:56) 6:44 (5:51, 7:10)
BMI, body mass index; CPAP, continuous positive airway pressure; ODI, Oxygen desaturation index >4%.
Figure 1 Kaplan- Meier curve showing the percentage of 
patients without the occurrence of a cardiovascular event 
by the number of follow- up days for standard care (dotted 
line) or CPAP solid line. Log rank p=0.54. Cox proportional 
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A theme consistent between MOSAIC, SAVE and the 
more recent Assessment of the Effect of CPAP on Energy 
and Vitality in Mild OSA (MERGE) trial, was the improve-
ment of quality of life and symptoms with CPAP in even 
mild OSA.1–3 5 It is notable that the average usage of 
CPAP at the end of long- term follow- up, among those 
who did continue treatment was good (>5 hour/night). 
This demonstrates that there are patients who adhere 
to CPAP in the long- term despite minimal symptoms. 
However, even among these individuals with good long- 
term adherence to CPAP there was no suggestion of a 
reduction in cardiovascular events.
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